Frontiers in Nutrition: Weight-loss drugs may change the desire to eat rather than the taste of food

Medications based on glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used to treat obesity, may alter people's relationship with food by changing how rewarding it feels rather than by affecting the sense of taste itself, according to a review published in Frontiers in Nutrition.

Many people taking GLP-1RA medications report that their favorite foods become less appealing, eating is less enjoyable, and cravings for high-calorie foods decrease. However, researchers suggest these changes do not necessarily reflect alterations in taste perception.

The review proposes that eating behavior should be considered as three distinct but interconnected components: sensory perception, food enjoyment, and motivation to eat.

The first component involves the ability to perceive the taste, smell, and texture of food. The second refers to the pleasure derived from eating, which depends not only on taste but also on previous experiences, emotions, and the body's physiological state. The third relates to the desire to seek out and consume specific foods.

According to the researchers, GLP-1RAs primarily influence the brain's reward and motivational systems rather than directly affecting taste receptors. Studies suggest that, in some people, these medications reduce cravings for energy-dense foods and decrease the brain's response to food-related cues.

The authors also note that common side effects—including nausea, early satiety, and delayed stomach emptying—may influence how food is experienced. As a result, it can be difficult to distinguish true changes in taste from a reduced enjoyment of eating.

The researchers emphasize that the available evidence remains mixed. Many existing studies were not specifically designed to examine changes in food perception, and patients' reports of "taste changes" may actually reflect different phenomena, including reduced appetite or gastrointestinal discomfort.

According to the review, distinguishing whether patients experience changes in taste perception, food enjoyment, or motivation to eat could help clinicians provide more personalized dietary guidance during obesity treatment.

The authors conclude that longer-term studies are needed to simultaneously evaluate taste perception, brain reward mechanisms, food preferences, and adherence to therapy.

Overall, the evidence suggests that, for most patients, changes in eating behavior during GLP-1RA treatment are more likely to result from altered food reward and motivation than from changes in taste itself.

Follow NEWS.am Medicine on Facebook and Twitter